immune disorders, inflammation, cancer, and cardiovascular disease (3 ). Such high concentrations of circulating adhesion molecules may be of interest for diagnostic and prognostic purposes, as demonstrated for ICAM-1 and P-selectin, which provide useful information in healthy individuals and in patients with cardiovascular diseases (9 ). However, reference values for healthy children and adults have not been defined.
Zymographic Analyses and Measurement of Matrix
. Healthy breast tissue synthesizes several MMPs (6 -8 ) , but in malignant lesions the tumor cells (as well as myoepithelial and stromal cells) are the main source of MMP-2 and -9, making them potentially useful cancer biomarkers (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . The influence of MMP inhibitors (12, 21 ) and the interactions between stromal and epithelial cells (22 ) may regulate the mechanisms of ECM degradation in breast tissue. Analysis of nipple aspirate fluids (NAFs) has attracted considerable interest as a method to assess metabolic activity within the mammary gland (23, 24 ) . In type II NAFs (indicative of premalignant disease), "abnormal" biosynthetically active apocrine cells (25, 26 ) are associated with exogenous/endogenous compounds involved in early malignant transformation (23, 26 -30 ) . Little information is available about proteolytic enzymes in NAF.
To investigate the ability of breast cells to produce and/or accumulate gelatinases and to evaluate their diagnostic accuracy, we studied molecular forms of MMP-2 and MMP-9 in NAF subtypes, evaluating their concentrations by immunoassay and their isoform distribution by gelatin zymography (31 ) .
Of 115 women participating in a breast cancer (BC) prevention trial at the Centre of Senology (1998 -2002), we excluded 30 patients reporting pregnancy or breast alterations within 3 years before the study or who were medically or surgically treated during the previous year. NAFs were prospectively collected from the remaining 85 nonlactating women (age range, 34 -47 years): 45 patients with benign breast disease (BBD; diagnosed by echographic and/or mammographic approaches), 5 patients with BBD at the time of NAF collection who subsequently developed BC, 12 patients with infiltrating ductal carcinoma diagnosed by surgical biopsy, and 23 women as healthy controls.
NAFs (20 -600 L) were centrifuged at 19 000g for 20 min at 4°C, and after removal of the lipid layer, the supernatant was analyzed for protein and MMP content (26 ) . Gelatin zymography was carried out on 7.5% polyacrylamide gels copolymerized with 2 g/L 90 Bloom Type A gelatin from porcine skin (Sigma) (32 ) .
After electrophoresis, gels were washed in Triton X-100 (25 mL/L) and incubated for 24 h (37°C) in enzyme buffer (containing, per liter, 50 mmol of Tris-HCl, pH 7.5; 5 mmol of CaCl 2 ; 100 mmol of NaCl; 1 mmol of ZnCl 2 ; 0.2 g of Brij ® -35; 2.5 mL of Triton X-100; and 0.02 g of NaN 3 ) (32 ). Zymograms were incubated in the presence of 5 mmol/L EDTA and 2 mmol/L 1,10-phenanthroline for inhibition studies (31 ); activation of zymogens was achieved with 2 mmol/L p-aminophenyl-mercuric acetate (31 ) . Staining was performed in Coomassie brilliant blue R-250 (2 g/L), and gels were destained appropriately (32 ) . Aliquots containing 150 g of total protein were used. Gelatinolytic bands were measured densitometrically with an image analyzer (Cybernetics) (33 ) . Gelatinase calibrators were prepared by diluting healthy capillary blood with 15 volumes of nonreducing sample buffer (containing, per liter, 62.5 mmol of Tris-HCl, pH 6.8; 350 mL of glycerol; 25 mL of Triton X-100; 40 g of sodium dodecyl sulfate; 0.2 g of Brij-35; 0.02 g of NaN 3 ; and 0.1 g of bromphenol blue) (34 ) .
We followed a previously described Western blotting protocol (35 ) throughout, using anti-human MMP-2 (clone 75-7F7) and MMP-9 (clone GE-213) monoclonal antibodies (Calbiochem).
Biotrak TM MMP-2 and -9 systems (Amersham-Pharmacia) were used for NAF and heparin plasma gelatinase determinations. The assay recognizes the proforms and active forms, does not cross-react with other MMPs, and shows cross-reactivity for MMP-tissue inhibitor of metalloproteinase complexes (36 ) . The detection limits were estimated as 0.5 and 0.25 g/L for MMP-2 and MMP-9, respectively.
To exclude NAF "matrix" artifacts caused by interfering substances, we serially diluted randomly selected samples (n ϭ 10) and reanalyzed them for the response linearity. We also determined the analytical recovery of three concentrations of purified proMMP-2 and -9 (Amersham-Pharmacia) added to the NAFs (35 ) .
For thermal stability studies, we incubated aliquots of NAFs (n ϭ 5) at different temperatures (45-85°C) for 30 min (30 ) .
Differences in the densitometric analyses of gelatinolytic activity in zymograms and between the mean of MMPs among NAF subtypes were determined by Student t-test and Mann-Whitney nonparametric U-test, using Prism 3 software (GraphPad). P Ͻ0.05 was considered significant.
The present work was carried out in accordance with the ethical standards of the Helsinki Declaration of 1975, as revised in 1983.
The linearity and interference studies revealed squared correlation coefficients (r 2 ) between MMP concentrations and dilution of 0.97 and 0.94 for MMP-2 and MMP-9, respectively, suggesting that the NAF matrix did not affect the performance of immunoassays.
The mean (SE) recoveries of purified MMPs added to NAFs were 92 (5)% and 95 (7)% for MMP-2 and MMP-9, respectively. Intra-and interassay CVs were 5% and 12% for MMP-2 and MMP-9, respectively.
Using a previous classification (26, 28, 30 ) , we subdivided the NAFs as type I (23 healthy and 45 BBD-affected women) and type II (12 BC patients and 5 women originally diagnosed for BBD who subsequently developed BC).
As shown in Table 1 , the mean MMP-2 in type I NAFs (healthy women and women with BBD; n ϭ 68) was significantly lower than that in type II NAFs from BC patients (n ϭ 17; P Ͻ0.005). We also found a significant difference between BBD and BC patients [244 (23) g/L in BBD (n ϭ 45) vs 336 (26) g/L in BC (n ϭ 17); P Ͻ0.005].
MMP-9 concentrations were higher in NAFs from women with BBD than in healthy controls [232 (27) respectively). Type I NAFs contained significantly lower MMP-9 than type II NAFs (P Ͻ0.001).
In NAFs (n ϭ 5) from patients diagnosed as BBD who subsequently developed BC, the mean (SE) concentrations were 291 (26) g/L and 365 (32) g/L for MMP-2 and MMP-9, respectively (P Ͻ0.001 vs controls and P Ͻ0.01 vs BBD patients).
Gelatin zymography detected all blood circulating gelatinases [72-kDa fibroblast-derived proMMP-2 and 92-, 130-, and 225-kDa neutrophil-derived proMMP-9 (33, 34 ) ] biochemically and immunologically demonstrated to be MMP-2 and MMP-9 (Fig. 1A) .
Zymography of type I NAFs (n ϭ 68) revealed four gelatinolytic bands, with molecular masses similar to those obtained for gelatinases from capillary blood, that were biochemically inhibited by EDTA and 1,10-phenanthroline (Fig. 1B) , were demonstrated immunologically to be MMP-2 and -9, and accumulated in NAFs as zymogens (see Fig. 1 , panels a and b, in the Data Supplement that accompanies the online version of this Technical Brief at http://www.clinchem.org/content/vol49/issue10/). The 92-kDa gelatinase B appears to be the constitutive MMP form. Zymograms obtained from type II NAFs (n ϭ 17) showed mainly two bands (92 and 72 kDa) with gelatinolytic activity that was inhibited by cation chelators (Fig.  1C) , with gelatinase A as the constitutive form. p-Aminophenyl-mercuric acetate activation and Western blot analyses demonstrated that the gelatinases in type II NAFs were the proforms and activated forms of MMP-2 and -9 ( Fig. 1, panels c and d , in the online Data Supplement).
NAFs from BBD patients who subsequently developed BC showed additional gelatinolytic bands (activated forms of both gelatinase A and B; Fig. 1C, lanes 2 and 4) .
Densitometrically, the gelatinase concentrations appeared to be two-to fourfold higher in type II NAFs than in type I NAFs (P Ͻ0.01).
Comparing gelatinases in NAFs from the BBD or BC breasts of patients with the contralateral healthy breasts (n ϭ 6), we found that the higher MMP concentrations and peculiar zymograms of type II NAFs may better represent a local process of higher biosynthetic activity.
Residual gelatinolytic activity was ϳ70% after 30 min at 55°C and ϳ20% at 65°C; MMP forms were not altered.
In this study, we found that NAFs contain MMP-2 and -9 and that both are significantly higher in type II NAFs collected from cancer-bearing patients than in type I from healthy and BBD-affected women; moreover, zymography revealed gelatinase profiles related to the pathologic state. Type I NAFs (healthy and BBD women) showed the same MMP forms circulating in blood, suggesting a mechanism of passive plasma filtration. In type II NAFs (cancer-bearing patients), we detected mainly two strongly expressed MMPs, the possible source being an active synthesis by breast cells and accumulation in NAFs in both the zymogenic and activated forms.
Our results (higher concentrations of gelatinase A in type I NAFs from healthy and BBD tissue) are in agreement with findings of MMP production/secretion in healthy breast tissue (3, 4, 6, 20, 22 ) . Although the physiologic roles of MMPs in the breast are not completely understood, our results may be related to the remodeling functions of breast in toto (3, 22 ) .
Related to MMPs synthesis/secretion by neoplastic and stromal cells, extensive ECM remodeling in breast tissue occurs during cancer initiation and progression (3, 5, 7-9, 13, 14, 19 ) . Our findings of strong expression for the proforms and active forms of MMP-2 and -9 in type II NAFs are in agreement with the involvement of cancer cells in enhanced gelatinolytic activity during neoplastic evolution (4, 11, 19 ) .
Although the origin of NAF gelatinases is unknown, we suggest that accumulation of pro-and activated forms of MMPs in type II NAFs may derive from the highly metabolizing apocrine cells (26, 29, 37 ) , representing a potential cancer biomarker with diagnostic accuracy. The production and/or secretion by breast cells of several proteolytic enzymes (26, 29, 37 ) and biologically active targets for MMP activity (3 ), in association with a lack of physiologic control of the NAF secretion/reabsorption mechanism (23 ) and with prolonged exposure to several biologically active substances through the autocrine/ paracrine mechanism (27 ) , could, with age, make the biosynthetically active apocrine NAF cells prone to premalignant transformation (25) (26) (27) . Biomolecular evaluation of the balance between MMP activity and MMP inhibitors (21, 38 ) may clarify the biological mechanisms of gelatinases during early neoplastic transformation (3, 4 ) .
